Indications for and outcome in patients with the wearable cardioverter-defibrillator in a nurse-based training programme: results of the Austrian WCD Registry

  • Tanja Odeneg
  • , Christian Ebner
  • , Deddo Mörtl
  • , Hans Keller
  • , Alfred Dirninger
  • , Günter Stix
  • , Bernhard Föger
  • , Georg Grimm
  • , Clemens Steinwender
  • , Franz Gebetsberger
  • , Markus Stühlinger
  • , Bernadette Mastnak
  • , Christian Haider
  • , Martin Manninger
  • , Daniel Scherr

Research output: Journal article (peer-reviewed)Journal article

Abstract

BACKGROUND: The wearable cardioverter-defibrillator is a treatment option for patients at temporarily high risk of sudden cardiac death or in whom implantation of a cardioverter-defibrillator is temporarily not possible.

OBJECTIVES: The aim of this study was to provide real-world data on patients receiving this therapy in a nurse-based wearable cardioverter-defibrillator training programme.

METHODS: A registry including all patients prescribed with a wearable cardioverter-defibrillator in Austria between 2010 and 2016. Overall, 448 patients received a wearable cardioverter-defibrillator in 48 centres. Patients received structured nurse-based wearable cardioverter-defibrillator educational initial training followed by remote monitoring.

RESULTS: Main indications were: severe non-ischaemic cardiomyopathy (21%); recent myocardial infarction and percutaneous coronary intervention (20%); and stable coronary artery disease with percutaneous coronary intervention/coronary artery bypass grafting (14%). Eleven patients (2.5%) received 22 appropriate wearable cardioverter-defibrillator shocks. Two patients (0.4%) received three inappropriate shocks. The risk of sudden cardiac death varied between different aetiologies. Eight out of 11 (73%) patients received their first wearable cardioverter-defibrillator shock within 30 days. The main reasons for termination of the wearable cardioverter-defibrillator therapy were implantable cardioverter-defibrillator implantation (55.5%) and improvement of left ventricular ejection fraction to more than 35% (33%).

CONCLUSION: The wearable cardioverter-defibrillator is an effective and safe treatment option in patients at either transiently elevated risk of ventricular tachycardia/ventricular fibrillation or mandated postponed implantable cardioverter-defibrillator implantation, with a 2.5% shock rate over a median 54 days wearable cardioverter-defibrillator treatment period. However, both the wearable cardioverter-defibrillator shock rate and implantable cardioverter-defibrillator implantation rate vary widely depending on the wearable cardioverter-defibrillator indication. Nurse-based wearable cardioverter-defibrillator training is associated with high patient adherence, with a median wearing duration per day of 23.5 (1-24) hours.

Original languageEnglish
Pages (from-to)75-83
Number of pages9
JournalEuropean Journal of Cardiovascular Nursing
Volume18
Issue number1
DOIs
Publication statusPublished - 01 Jan 2019

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Adult
  • Aged
  • Aged, 80 and over
  • Arrhythmias, Cardiac/therapy
  • Austria
  • Female
  • Humans
  • Male
  • Middle Aged
  • Patient Compliance/psychology
  • Patient Education as Topic/statistics & numerical data
  • Registries
  • Time Factors
  • Treatment Outcome
  • Wearable Electronic Devices/psychology

Fingerprint

Dive into the research topics of 'Indications for and outcome in patients with the wearable cardioverter-defibrillator in a nurse-based training programme: results of the Austrian WCD Registry'. Together they form a unique fingerprint.

Cite this